Short form 1b human prolactin receptor down-regulates expression of the long form

Journal of Molecular Endocrinology

Volumn 44, Issue 3, 2010, Pages 187-197

  Tan, Dunyong ^a   Walker, Ameae M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN; HYGROMYCIN; LUCIFERASE; MESSENGER RNA; PROLACTIN RECEPTOR;

ARTICLE; CELL COUNT; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MESSENGER RNA SYNTHESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ALTERNATIVE SPLICING; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOMEGALOVIRUS; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN ISOFORMS; RECEPTORS, PROLACTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 76649088316     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1677/JME-09-0101     Document Type: Article

References (26)

1. Ben-Jonathan N, Liby K, McFarland M & Zinger M 2002 PRL as an autocrine/paracrine growth factor in human cancer. Trends in Endocrinology and Metabolism 13 245-250.
2. Ben-Jonathan N, LaPensee CR & LaPensee EW 2008 What can we learn from rodents about prolactin in humans? Endocrine Reviews 29 1-41.
3. Berlanga JJ, Garcia-Ruiz JP, Perrot-Applanat M, Kelly PA & Edery M 1997 The short form of the prolactin (PRL) receptor silences PRL induction of the beta-casein gene promoter. Molecular Endocrinology 11 1449-1457.
4. Brockman Jl & Schuler LA 2005 Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Molecular and Cellular Endocrinology 239 45-53.
5. Chen TJ, Kuo CB, Tsai KF, Liu JW, Chen DY & Walker AM 1998 Development of recombinant human prolactin receptor antagonists by molecular mimicry of the phosphorylated hormone. Endocrinology 139 609-616.
6. Clevenger CV, Rycyzyn MA, Syed F & Kline JB 2001 Prolactin receptor signal transduction. In Prolactin, pp 355-379. Ed ND Horseman. Boston: Kluwer Academic publishers.
7. Cosman D 1993 The hematopoietin receptor superfamily. Cytokine 5 95-106.
8. Gadd SL & Clevenger CV 2006 Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Molecular Endocrinology 20 2734-2746.
9. Grotzinger J 2002 Molecular mechanisms of cytokine receptor activation. Biochimica et Biophysica Acta 1592 215-223.
10. Hu ZZ, Meng J & Dufau ML 2001 Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of newly identified exon 11. Journal of Biological Chemistry 276 41086-41094.
11. Huang Kuang Tzu, Chen Yen Hao & Walker Ameae M 2004 Inaccuracies in MTS assays: major distorting effects of medium, serum albumin, and fatty acids. BioTechniques 37 406-412.
12. Kline JB, Roehrs H & Clevenger CV 1999 Functional characterization of the intermediate isoform of the human prolactin receptor. Journal of Biological Chemistry 274 35461-35468.
13. LaVoie HA & Witorsch RJ 1995 Investigation of intracellular signals mediating the anti-apoptotic action of prolactin in Nb2 lymphoma cells. Proceedings of the Society for Experimental Biology and Medicine 209 257-269.
14. Leav I, Merk FB, Lee KF, Loda M, Mandoki M, McNeal JE & Ho SM 1999 Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. American Journal of Pathology 154 863-870.
15. Lee KF, Atiee SH & Rosen JM 1989 Differential regulation of rat β-casein-chloramphenicol acetyltransferase fusion gene expression in transgenic mice. Molecular and Cellular Biology 9 560-565.
16. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B et al. 2004 Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Research 64 4774-4782.
17. Meng J, Tsai-Morris CH & Dufau ML 2004 Human prolactin receptor variants in breast cancer:low ratio of short forms to the long form human prolactin receptor associated with mammary carcinoma. Cancer Research 64 5677-5682.
18. Meyer S, Temme C & Wahle E 2004 Messenger RNA turnover in eukaryotes: pathways and enzymes. Critical Reviews in Biochemistry and Molecular Biology 39 197-216.
19. Peirce SK & ChenWY 2004 Human prolactin and its antagonist, hPRLG129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 23 1248-1255.
20. Qazi AM, Tsai-Morris CH & Dufau ML 2006 Ligand-independent homo- and heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Molecular Endocrinology 20 1912-1923.
21. Tan D, Johnson DA, Wu W, Zeng L, Chen YH, Chen WY, Vonderhaar BK & Walker AM 2005 Unmodified prolactin (PRL), and S179D PRL-initiated bioluminescence resonance energy transfer between homo- and hetero-pairs of long and short PRL receptors in living human cells. Molecular Endocrinology 19 1291-1303.
22. Tan D, Huang KT, Ueda E & Walker AM 2008 S2 deletion variants of human prolactin receptors demonstrate that extracellular domain conformation can alter conformation of the intracellular signaling domain. Biochemistry 47 479-489.
23. Tay Y, Zhang J, Thomson AM, Lim B & Rigoutsos I 2008 MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 455 1124-1128.
24. Trott JF, Hovey RC, Koduri S & Vonderhaar BK 2003 Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted PRL-binding protein. Journal of Molecular Endocrinology 30 31-47.
25. Walker AM 2005 Prolactin receptor antagonists. Current Opinion in Investigational Drugs 6 378-385.
26. Wu W, Ginsburg E, Vonderhaar BK &Walker AM 2005 S179D prolactin increases vitamin D receptor and p21 through upregulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Research 65 7509-7515.